Question 1

What is ARD-101?

Accepted Answer

ARD-101 is a Other.

Question 2

How often does ARD-101 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was ARD-101 first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was ARD-101 last mentioned in news?

Accepted Answer

Last active on May 26, 2026.

Question 5

What is ARD-101's current news sentiment?

Accepted Answer

Aggregate sentiment score: -80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ARD-101 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ARD-101?

Accepted Answer

Pomerantz Investigates Aardvark Therapeutics Securities Fraud (May 21, 2026, 6 articles).

Question 8

How did the "Pomerantz Investigates Aardvark Therapeutics Securities Fraud" event impact ARD-101?

Accepted Answer

ARD-101 is the investigational drug developed by MiNK Therapeutics, which is now under a full clinical hold by the United States — Food and Drug Administration, severely impacting its development and market potential.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.